A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
WSAU

Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial

An experimental drug developed by China-based Akeso helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' immunotherapy Tevimbra, and cut the risk ...
The Manila Times

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung ...

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 ...

Lung cancer patients on drug from China’s Akeso lived longer

A lung cancer drug developed by Akeso Inc. extended patients’ lives by about four months in a late-stage trial in China, ...
STAT

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Matthew Herper covers medical innovation — both its promise and its perils. CHICAGO — Ivonescimab, a drug that combines the activity of two of the best-selling cancer medicines, reduced the risk of ...

Lilly says Retevmo cuts lung cancer recurrence risk in late-stage trial

Eli Lilly (LLY) said its targeted cancer therapy Retevmo significantly reduced the risk of disease recurrence or death in patients with early-stage RET fusion-positive non-small cell lung cancer, ...

BioNTech SE: Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ...

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 ...

New dual-action drug a ‘promising step forward’ for patients with hard-to-treat lung cancer

Experts have described the findings as a ‘promising step forward‘ for patients with advanced squamous non-small cell lung cancer ...
Fierce Biotech

In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach

In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...
The Manila Times

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically ...

Salubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the 2026 American Society of Clinical Oncology Annual Meeting

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced updated data from the ...

Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's trophoblast ...